Clinical Trial Transparency To Move Up A Notch In UK

HRA To Build Sanctions Into Its Study Approvals Process

The UK Health Research Authority has adopted a new strategy to give more teeth to its statutory objective of driving improvements in research transparency.

Clinical trials
HRA Plans To Measure Transparency Performance Of Individual Sponsors • Source: Shutterstock

The Health Research Authority has unveiled its much-awaited strategy on how it plans to improve clinical trial transparency in the UK with provisions that will introduce “fair consequences for those who don’t take transparency seriously.”

Under the “Make it Public” strategy, the HRA intends to introduce, among other things, a new system in 2021-22 of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United Kingdom

UK MHRA Ready To Evolve Approach To In-House Manufactured Medtech

 
• By 

The UK device regulator wants to align health institution device exemptions with its evolving policy of agile regulation of medtech in the British market. It asks stakeholders to complete a survey by Sept. 15.

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

HistoSonics Sells Majority Stake To Investor Syndicate In Deal Valued At $2.25Bn

 
• By 

HistoSonics’ CEO Michael Blue describes the deal as a win-win for all stakeholders and plans to use the money to expand clinical indications, as well as the global reach, for its Edison system.

Ultromics Wins $55M, The Key To Success: Diagnosing Diseases With Available Treatment

 

Ultromics has secured $55m in Series C funding to advance its AI tool, EchoGo, which detects undiagnosed heart failure. The company's focus on diseases with available treatments resonated with investors.

More from Europe

EU4Health Boost For Orphan Devices And SMEs

 
• By 

EU4Health, the main funding instrument for EU health initiatives, has put renewed emphasis on orphan devices in its 2025 work program, published in July.

Swiss Medtech To Battle ‘Arbitrary’ 39% US Tariff

 
• By 

In return for building a successful US export business, Switzerland has been handed a 39% tariff effective immediately by the Trump administration. Diplomatic channels have been reopened to undo the tariff. Meanwhile, the medtech industry is looking to develop OUS markets for Swiss exporters.

HistoSonics Sells Majority Stake To Investor Syndicate In Deal Valued At $2.25Bn

 
• By 

HistoSonics’ CEO Michael Blue describes the deal as a win-win for all stakeholders and plans to use the money to expand clinical indications, as well as the global reach, for its Edison system.